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Abstract: The chronicity of asthma results not only in persistent lung inﬂ  ammation but 
also in changes in structure and composition of this vital organ. These changes are most 
commonly referred to as remodeling, and include epithelial dysplasia, angiogenesis, changes 
in the extracellular matrix and increased smooth muscle mass. In this review we summarize 
recent ﬁ  ndings on the contribution of remodeling to the pathological phenotype of asthma. 
We discuss how and why current treatment (such as corticosteroids) options fail to adequately 
treat remodeling.
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Asthma
Asthma is a chronic inﬂ  ammatory disease of the airways, characterized by reversible 
airﬂ  ow obstruction. In addition to chronic inﬂ  ammation, the asthmatic airways have 
several structural changes, such as increased smooth muscle mass, differences in the 
extracellular matrix composition, increased vascularity and epithelium dysfunction. 
Collectively these changes are known as remodeling, and are thought to contribute to the 
airways’ increased ability to respond to a wide range of stimuli (hyper-responsiveness). 
Bronchial hyper-responsiveness (BHR) is quantiﬁ  ed as the change in lung function, due 
to airway constriction, invoked by a range of agents. Agents are either non-speciﬁ  c, such 
as pharmacologically or chemically active molecules, or physical or physiochemical 
agents. Agents can also be speciﬁ  c, for example allergens. Worldwide the prevalence 
of asthma is increasing; however it remains to be seen if the increased prevalence 
observed over the last century continues.1,2 This may in part be due to better training 
of the medical community to recognize the symptoms of asthma, and the increase in 
environmental irritants and allergens such as the house dust mite.
Pathology of asthma
In 1922, a landmark study was carried out by Huber and Koessler on the airways of 
21 patients who had died of asthma and seven patients who had died from other causes. 
The major ﬁ  ndings from their report are still relevant today, in that they found that in 
bronchi with an external diameter of greater than 2 mm, the subepithelial layer, the 
smooth muscle layer and the total wall thickness were all increased.3 Endobronchial 
biopsies have conﬁ  rmed that non fatal asthma is an inﬂ  ammatory disease.4–6 Laitinen 
and others (1985) carried out a bronchoscopic study of various sites within the lungs 
of asthmatic subjects, and found that inﬂ  ammation and tissue destruction were 
apparent at all sites sampled.7 In addition the inﬂ  ammatory gene expression proﬁ  le 
has been shown to be different in asthma using in-situ hybridization,8 and furthermore 
the speciﬁ  c source and expression of various cytokines differs in asthmatic tissue.9 
Eosinophilia has for many years been considered a distinguishing feature of asthma, Journal of Asthma and Allergy 2009:2 34
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however eosinophilia has also been observed in other airways 
diseases such as eosinophilic bronchitis. Recently a report 
by Brightling et al highlighted the possible importance of 
mast cells located within smooth muscle bundles of subjects 
with asthma. Mast cell inﬁ  ltration of the smooth muscle layer 
was found to be signiﬁ  cantly higher in asthmatic subjects 
when compared to non-asthmatics, and to subjects with 
eosinophilic bronchitis.10 However mast cells located in the 
smooth muscle bundles may not be a distinguishing feature 
of asthma since this was also found in patients with chronic 
obstructive pulmonary disease (COPD) and subjects who 
were currently smoking.11,12 The role of the neutrophil in the 
pathology of asthma has for the most part been overlooked. 
Recent reports demonstrate that neutrophilia occurs in certain 
situations. Analysis of sputum from asthmatics reveals 
elevated numbers of neutrophils during exacerbation.13 This 
may however more likely reﬂ  ect the immune response to 
respiratory tract infections and as such may not be a feature 
of stable asthma. On the other side, neutrophilia is also 
observed in sudden onset fatal asthma,14 indicating the role of 
the neutrophil in more severe manifestations of the disease. 
A report by Wenzel and co-workers found neutrophilia to be 
present in severe asthmatics that had been treated for ﬁ  ve or 
more years with high doses of oral steroids, when compared 
to non-asthmatics and mild asthmatic subjects requiring 
treatment with inhaled β agonists alone.15 It is not known if 
neutrophilia observed in asthma is due to corticosteroid treat-
ment alone, since corticosteroids reduce eosinophil numbers 
and inhibit neutrophil apoptosis.16 It is conceivable that the 
neutrophilia observed in asthma is due to factors other than 
steroid use or respiratory infection.
Airway remodeling
Histological examination has demonstrated that in asthma 
the airway wall is thickened, due to epithelial dysplasia, 
angiogenesis, increased extracellular matrix (ECM) 
deposition, and increased airway smooth muscle (ASM) 
mass; collectively termed remodeling. Increased mucous and 
mucous plugs are found in the asthmatic airways. This cannot 
only physically occlude the airways, but can increase the air-
way surface tension promoting airway collapse. Aikawa and 
colleagues (1992) carried out necroscopic morphometric 
analysis of subjects’ lungs who had died from an asthma 
attack in comparison to lungs from subjects with asthma who 
had died of other causes. A 30-fold increase in goblet cells 
and a three-fold increase in mucous production were observed 
in fatal asthma.17 Furthermore the mucin composition of 
mucous is altered in tissues from patients with fatal status 
asthmaticus in comparison to milder asthma, with an increase 
of mucin (MUC) gene 5 subtype AC and MUC5B found on 
the luminal side of the epithelium. In contrast, these were not 
present at this location in non-asthmatic tissue.18
Remodeling is a consistent feature of both fatal and milder 
manifestations of asthma. A report by Roche and colleagues 
described thickening below the basement membrane due to 
collagen deposition, and not increased basement membrane 
thickness as previously believed.19 The increased collagen 
deposition was not due to epithelial dysfunction, and is 
most likely due to ﬁ  broblast activation. This, as Roche and 
colleagues pointed out, is more correctly called subepithelial 
ﬁ  brosis.19 The subepithelial ﬁ  brosis is due to deposition of 
collagens type I, III, and V.
Smooth muscle cell remodeling
In 2004, Mitzner asked the question: “Airway smooth 
muscle: the appendix of the lung”? In this paper, Mitzner 
postulated that airway smooth muscle is a worthless struc-
ture with no essential physiological function that can lead 
to serious medical problems. Airway smooth muscle is 
largely involved in the bronchial remodeling that occurs 
in asthma.10,20–23 Many studies show an increase in airway 
smooth muscle mass in fatal asthma.20,24,25 Trian et al23 
examined bronchus from severe asthmatics, (GINA 4)26 
using specimens from biopsies, and showed an increase in 
smooth muscle area compared to non-asthmatics. However, 
this increase of airway smooth muscle mass has also been 
shown in non-fatal asthma, ie, mild and moderate. Carroll 
et al examined bronchial tissue from fatal asthma, those dying 
of other causes with a history of asthma (mild and moderate 
asthma) and those who died of other causes without any 
history of respiratory disease.27 They found a greater area of 
smooth muscle in the cartilaginous airways of fatal asthma 
compared to non-fatal and non-asthmatic. The inner wall area 
was greater in the fatal and non-fatal cases than in the control 
cases in the small cartilaginous airways and membranous 
bronchioles (MB). In small MB (perimeter 2 mm), the 
total and outer wall areas were greater (p  0.05) in cases of 
fatal and non-fatal asthma than in control cases. Remodeling 
of the smooth muscle layer has a key role as an important 
effector of the pathology of asthma. For example, there is a 
correlation between BHR early phase amplitude and smooth 
muscle mass.28
Asthmatic smooth muscle remodeling is also characterized 
by an increase of extracellular matrix between smooth muscle 
cells. In a recent study, Begueret et al examined biopsies 
from severe asthmatics using electron microscopy.29 In this Journal of Asthma and Allergy 2009:2 35
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study, the authors found a higher degree of organization of the 
extracellular matrix between airway smooth muscle cells.
However, all these studies need to be viewed cautiously 
because ASM mass is quite difﬁ  cult to measure due to 
problems in obtaining biopsies. Quantiﬁ  cation of smooth 
muscle mass increase in asthma needs the involvement of 
new technology to assess speciﬁ  cally smooth muscle mass 
such as quantitative morphometry and/or laser dissection.30 
Due to the difﬁ  culty in obtaining and assessing smooth 
muscle remodeling in asthma using human biopsies, many 
studies have been done using animal models. Using long-
term ovalbumin sensitization models, smooth muscle asthma 
remodeling can be found, with an increase of the smooth 
muscle mass. Moreover, McMillan et al found that prolonged 
allergen challenge using ovalbumin in mice leads to persistent 
airway remodeling.31
Other changes in smooth muscle 
layer in asthma
As mentioned above, asthmatic smooth muscle features an 
inter-cellular increase of extracellular matrix. This increase 
of matrix seems to be an important characteristic. In a recent 
study, Slats32 found that airway hyperresponsiveness, FEV1% 
predicted, and airway responses to deep inspiration are 
associated with components of the extracellular matrix.32 In 
2004, Johnson et al showed that an external protein matrix could 
modulate ASM proliferation in asthma.21 Another recent study 
using bovine tracheal smooth muscle shows that extracellular 
matrix proteins differentially regulate both phenotype and func-
tion of intact ASM in terms of contraction and proliferation.33
According to the literature, the mechanism of smooth 
muscle remodeling seems to involve both hyperplasia and 
hypertrophy. Indeed, there are some studies which involve 
hypertrophy in the increase of airway smooth muscle cell 
mass in asthma.20,34,35 In a recent study, Trian et al suggested 
that the increase of smooth muscle cell proliferation in 
asthma, previously shown by Johnson et al was due to an 
increase of mitochondrial mass in asthmatic airway smooth 
muscle.23 This increase of mitochondrial mass was found 
only in smooth muscle cells and only in severe asthmatic 
patients. In this paper, the authors also explained this increase 
by a deregulation of the mitochondrial biogenesis, with an 
up-regulation found in asthmatic airway smooth muscle cells. 
The cause of this activation seems to be a calcium deregulation 
involving the voltage operated channels (VOCs).
However, in an asthmatic bronchus there are many other 
factors that can induce smooth muscle cell proliferation 
(see Table 1). For example, one of the other characteristics 
of the smooth muscle layer remodeling that occurs in asthma, 
is the speciﬁ  c inﬁ  ltration of mast cell.10 Airway smooth 
muscle layer mast cells found in asthma are in an activated 
state, primed to release mediators.29 One of these mediators, 
mast cell tryptase has been shown to be an activator of smooth 
muscle proliferation in vitro.36 This activation of ASM via 
the protease activated receptor 2 (PAR-2)37 is also involved 
in the secretion of TGFβ-1 and stem cell factor (SCF), two 
mast cell chemotactic factors that induce an activation loop 
between mast cell and ASM that could be involved in ASM 
remodeling by induction of smooth muscle cell (SMC) 
proliferation. Other factors have been shown to induce 
smooth muscle cell proliferation, for example, platelet derived 
growth factor (PDGF)38 or insulin-like growth factors 1 and 
2 (IGF-1 and IGF-2).39 Smooth muscle proliferation is also 
induced by the interaction and the close relationship between 
all the cell types in the bronchus. One of the examples is the 
relationship between mast cells and SMC described above, 
but there is also a close interaction between epithelial cells 
and smooth muscle cells. For example, bronchial epithelial 
cells can release epidermal growth factors which has been 
shown to have a potential mitogenic activity on bronchial 
airway smooth muscle cell.40 Finally, there is also another 
hypothesis to explain this increase in SMC mass suggested 
by Ramos-Barbon who found a decrease in SMC apoptosis 
in an asthmatic rat model.41
However, the mechanism of smooth muscle increase in 
asthma is still controversial. Begueret et al used immuno-
chemistry to assess the presence of Ki67 staining in airway 
smooth muscle cells. In this study, the authors could not 
ﬁ  nd any staining of Ki67.29 Moreover, many studies involve 
hypertrophic mechanisms in smooth muscle remodeling in 
asthma. In 2004 Zheng et al showed that treatment of guinea 
pig airway explants with cardiotrophin, a member of the 
IL-6 family induces an increase of size and protein content 
of airway smooth muscle cells.42 Furthermore, TGF-β, 
which is mostly involved in asthma pathophysiology, has 
been shown to induce hypertrophy and increase in protein 
synthesis in airway smooth muscle cells.43 In a recent study, 
Deng et al suggested that inhibition of the GSK-3β/eIF2B 
translational control pathway contributes to airway smooth 
muscle hypertrophy in vitro and in vivo. However, they also 
demonstrated that TGF-β-induced hypertrophy does not 
depend on GSK-3β/eIF2B signaling.44
Vascular remodeling
Another component of asthmatic airway remodeling is 
alteration to the vasculature of the lung, including blood Journal of Asthma and Allergy 2009:2 36
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and lymphatic vessels. The cardinal function of the lung, 
gas exchange, requires a vast network of blood vessels 
ranging from macro- to submicro vascular vessels. Another 
well-appreciated function of this network is the transport of 
nutrients45 and the exchange of heat and water.46 Additionally, 
the blood vessel system provides extensive tracks for 
progenitor cells as well as immune cells.47,48 Furthermore, 
active distribution of airborne substances throughout the 
body has been described (eg, pharmacological agents and 
antigens49,50). An extensive valve and vascular smooth muscle 
system allows an active responding vascular system.
The lymphatic system on the other hand is thought to 
be of a less complex construction than the blood vessels.51 
Simpler valve systems are supported passively by contraction 
and expansion of skeletal muscle or tissue.52 It is pro-
posed that this function is maintained through ﬁ  lamentous 
structures anchored at the adjacent tissue.52 Through this 
passive pump mechanism interstitial ﬂ  uid, containing among 
others lipids, proteins and cells, is drained away from the 
tissue. Accumulation of ﬂ  uid can occur due to vasodilation 
(eg, caused by histamine) and leakage of blood vessels. To 
prevent severe edema, this ﬂ  uid has to be drained away by 
the lymphatic system which therefore aids the collection of 
exogenous proteins such as inhaled antigens.53 In case of 
inﬂ  ammation the lymphatic system represents the collecting 
(afferent) network for dentritic cells (DC) charged with 
foreign material (antigens) to be presented in the proximal 
lymph nodes to generate an adaptive immune response.52,54 
Under healthy conditions accumulation and drainage 
represent a balanced process.55
Impaired growth of lymphatic vessels is reported to support 
bronchial lymphoedema in a mouse model of chronic lung 
inﬂ  ammation (Mycoplasma pulmonis).56 Due to inﬂ  ammation 
severe asthmatics experience mucosal edema, which may lead 
to further narrowing of the bronchial caliber, subsequently 
enhancing breathing difﬁ  culties.57,58 The current understanding 
of the importance of the lymphatic system in asthma is limited 
but it has recently gained more scientiﬁ  c interest.
Table 1 Factors inducing airway smooth muscle cell proliferation
Classiﬁ  cation Products Origin
Growth factors βFGF ECM, Monocyte, SMC
IGF-1 Epithelial cell, mesenchymal cell, macrophage
EGF Epithelial cell
NGF Eosinophil, ﬁ  broblast, epithelial cell, mast cell
PDGF Platelet, monocyte, SMC, epithelial cell
Inﬂ  ammatory products Elastase Neutrophil
β-Hexosaminidase Mast cell
Thrombin Platelet
Thromboxane A2 Platelet
Histamine Mast cell
Neutrophil elastase Neutrophils
Bradykinin Mast cell
Tryptase Mast cell
Cytokines IGF-1 Platelet, monocyte, SMC, epithelial cell
IL-1β Lymphocyte, monocyte, epithelial cell
IL-6 Lymphocyte, monocyte, SMC, epithelial cell
TNF-α Lymphocyte, monocyte, SMC, epithelial cell
TGF-β1 Lymphocyte, monocyte, SMC, platelet, ECM
Others Endothelin-1 Platelet, monocyte, epithelial cell
5-HT Platelet
Substance P Neuron, epithelial cell
ATP Mesenchymal cell
Extra cellular matrix Fibronectin Mesenchymal cell
Collagen I Mesenchymal cell
MMP-2 Endothelial cell, macrophage
Abbreviations: SMC, smooth muscle cell; ECM, extracellular matrix.Journal of Asthma and Allergy 2009:2 37
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The chronic inflammation occurring during asthma 
requires the support of the vascular system. In case of 
encounters with foreign material, DCs are charged with 
antigen and proceed to the lymph nodes for presentation. 
Replenishment with naïve DCs is maintained via the 
blood vessels. Additionally, to battle pathogenic viruses or 
bacteria the recruitment of activated leukocytes (neutrophils, 
eosinophils and macrophages) is achieved via the same 
gateway.
Resident structural cells such as lung epithelial cells (type 
I and II pneumocytes), smooth muscle cells and ﬁ  broblasts 
change expression proﬁ  les under inﬂ  ammatory conditions 
supporting the growth and extension of the vascular system. 
ASM are able to produce a wide range of both angiogenic and 
anti-angiogenic factors such as tissue inhibitor of metallo-
proteinase (TIMP) 1 and 2, thrombopoietin (TPO), ﬁ  broblast 
growth factor (FGF) and vascular endothelial growth factor 
(VEGF) (own unpublished data and Figure 1). VEGF has 
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Figure 1 Secretion of the anti-angiogenic factors into cell culture medium by airway smooth muscle cells:   TIMP-1 A), TIMP-2 B) as well as pro-angiogenic factors: VEGF 
C), TPO D), bFGF E). No statistical differences are observed between asthmatics (A) and non-asthmatics (NA). F) Treatment (+) with 10–8 M dexmethasone did not change 
signiﬁ  cantly the expression levels of VEGF in ASM (A or NA) after 24 h. n = 4 for all.Journal of Asthma and Allergy 2009:2 38
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been shown in moderate or severe asthmatics to be elevated 
in sputum and submucosa59 and so was FGF,60 leading to a 
possible extension of the peri-bronchial vascular system. 
Simcock and colleagues recently demonstrated increased 
expression of VEGF by asthmatic airway smooth muscle cells 
which induced tubule formation of endothelial cells.61 Our 
ﬁ  ndings support this, however as a trend only (Figure 1 D). 
Furthermore VEGF is a prominent and powerful modulator 
of endothelial proliferation.
The balance of angiogenic and anti-angiogenic stimuli 
is crucial and surely doesn’t rely solely on VEGF. How-
ever, the current understanding is not fully conclusive to 
how this balance is maintained. Interestingly it has been 
shown that in asthma an anti-angiogenic ECM component, 
derived from collagen XVIII α1 – endostatin – is reduced 
in steroid naïve asthmatics.59 Furthermore the levels of 
collagen IV are known to be decreased in the asthmatic 
lung,62 however, it is unknown which α – chain or chains 
are affected.
At least three of the collagen IV α-chain NC1 domains, 
α1–α3, have been reported to possess anti-angiogenic activity. 
Collagen IV α1 inhibits VEGF – induced proliferation and 
migration of endothelial cells through binding of the α1β1 
integrin.63 As for collagen IV α2, inhibition of endothelial 
cell proliferation and migration is suggested to be mediated 
by a cell surface protein/receptor, the most likely candidates 
being αvβ3, α1β1 and α2β1 integrins.64 Lastly, collagen IV 
α3 induces apoptosis of proliferating endothelial cells.65–67 
The mechanism of action is through the interaction with 
αvβ3 integrin, which leads to the inhibition of focal adhesion 
kinase (FAK), phosphatidylinositol (PI) −3 kinase, protein 
kinase B (Akt) and mammalian target of rapamycin (mTOR) 
as well as the prevention of the dissociation of the eukaryotic 
translation initiation factor 4E/eukaryotic initiation factor 
4E-binding protein 1 (eIF4E/4E-BP1) complex, resulting 
in the inhibition of cap-dependent protein translation in 
endothelial cells.68
Is remodeling important?
Asthma is characterized by reversible airﬂ  ow obstruction. 
While airﬂ  ow obstruction is often variable, it is now thought 
that it may not be fully reversible in all asthmatic patients 
due to chronic airway remodeling.69 Whether remodeling 
initiates the development of asthma or occurs secondarily is 
not known. In children with asymptomatic bronchial hyper-
responsiveness, longitudinal studies have demonstrated that 
the subsequent development of asthma is closely associated 
with the development of remodeling.70,71 In adults, the natural 
decline in airway function which occurs with age is known 
to occur at an increased rate in patients with asthma.72,73 
This accelerated loss of lung function is likely to be due to 
remodeling. Furthermore recent studies have shown that the 
severity of asthma clearly correlates with the presence of 
remodeling.74,75 In contrast, others have postulated that airway 
remodeling which results in a thickened airway wall may 
however protect against excessive airway narrowing.76
The etiology of remodeling
In vivo histological studies of airways from patients with and 
without asthma describe enhanced deposition of collagen I, 
III, and V, ﬁ  bronectin, tenascin, hyaluronan, versican, laminin 
α2/β2, lumican, and biglycan,77 whereas levels of collagen IV 
and elastin are decreased.77 Data from our group and others 
have demonstrated that the ECM produced by lung cells in 
vitro differs signiﬁ  cantly when cells from asthmatic and non-
asthmatic individuals are compared.78,79 The interaction of 
the ECM and lung cells is dynamic. In response to different 
ECM components, such as ﬁ  bronectin, collagen and perlecan, 
the proliferation, survival and inﬂ  ammatory mediator release 
from smooth muscle cells can be altered.80–83 Lung cells 
also possess the ability to modulate the surrounding ECM 
in response to factors such as physical stress and soluble 
mediators.77,84,85 Moreover, we have previously shown that 
the ECM produced by asthmatic cells can induce cells from 
non-asthmatic subjects to assume the characteristics of those 
from asthmatic subjects.77
Role of remodeling and inﬂ  ammation 
in the progression of asthma
It is not known if remodeling initiates inﬂ  ammation, or vice 
versa, in the airways of asthmatics. A recent study from 
Saglani et al demonstrated that neither remodeling nor 
inﬂ  ammation were present in atopic infants with reversible 
airﬂ  ow obstruction, whilst they did occur in older children.70 
However, in a longitudinal study in older children, both 
preceded the development of asthma.71 Chronic airway 
remodeling is likely to be the result of an aberrant repair cycle 
which occurs in response to chronic inﬂ  ammation.86 The 
interactions between many cell types, including epithelial 
cells, ﬁ  broblasts and smooth muscle cells play an important 
role in this process. The bronchial epithelium is a rich source 
of proﬁ  brotic growth factors, and it is likely that the interac-
tion between these and the underlying mesenchymal cells 
controls remodeling. Furthermore, some groups hypothesize 
that altered signaling in the “epithelial-mesenchymal trophic 
unit” drives chronic remodeling in asthma.86 It is likely that Journal of Asthma and Allergy 2009:2 39
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these mediators can act via both an autocrine and paracrine 
mechanism to increase remodeling.
Therapeutic options 
for the treatment of remodeling
Inﬂ  ammation can to some degree be treated in asthma, 
however the current therapeutic regimes may not reverse 
the remodeling process. Short term treatment of asthmatic 
subjects with steroids (6 weeks) can reduce the thickness 
of the basement membrane,87 however long term treatment 
with steroids (mean 3.1 years) did not reduce the total 
thickness of the airways when compared to non-steroid 
treated asthmatics.76
Recently leukotriene receptor antagonists have shown 
some therapeutic potential for the treatment of airway 
remodeling in asthma. In a murine model of allergic airways 
disease blockage of the CysLT1 receptor reduced allergen-
induced mucus plug formation, smooth muscle hyperplasia, 
and airway ﬁ  brosis (assessed by collagen deposition).88 
Interestingly, leukotriene receptor antagonists have also been 
shown to inhibit bleomycin-induced lung ﬁ  brosis in mice.89
Leukotriene receptor antagonists have also been shown 
to inhibit human lung myoﬁ  broblast proliferation ex vivo 
from patients with ﬁ  brotic lung diseases90 and there is some 
evidence that allergen-induced myoﬁ  broblasts are inhib-
ited in vivo following treatment with leukotriene recep-
tor antagonists in asthmatics.91 The mechanism of action 
by which leukotriene receptor antagonists inhibit airway 
remodeling is still not known, however since CysLTC4 
induces the production of TGFβ from epithelial cells92 pre-
sumably inhibition of the leukotriene receptor would result 
in decreased TGFβ production. However a recent study by 
Altraja et al suggests that leukotrienes induce the production 
of ECM proteins directly from epithelial cells adding further 
weight to the potential for leukotriene receptor antagonists 
to treat remodeling. Randomized controlled trials in humans 
examining the effect of leukotriene receptor antagonists upon 
airway remodeling in asthma have not been done; however 
a case report by Pifferi et al demonstrated the therapeutic 
potential of montelukast to reverse airway remodeling 
in children.93 We have shown that a phosphodiesterase 
4 inhibitor inhibited the deposition of extracellular matrix 
proteins ex vivo in human bronchus.94
There are no therapeutics available to reverse the 
increased airway smooth muscle that is observed in asthma. 
One potential reason why corticosteroids do not decrease the 
amount of airway smooth muscle in asthma was proposed 
by Roth et al.95 They demonstrated an abnormality in the 
corticosteroid receptor cofactor C/EBPα which results in 
the loss of antiproliferative effect of the corticosteroids on 
asthmatic smooth muscle cell proliferation.
Recently, however, a new technique has increased 
interest to ﬁ  nd therapeutics against smooth muscle cell 
remodeling in asthma. Laviolette‘s group,96,97 treated 
moderate to severe asthmatics using a bronchoscopic 
procedure, bronchial thermoplasty, to reduce ASM mass. 
In this study, the authors have shown that the reduction 
of ASM mass improves asthma control. Indeed, this 
“treatment” reduced exacerbation frequency, and increased 
morning peak expiratory ﬂ  ow and symptom scores. This 
study showed the importance of smooth muscle remodeling 
in the physiopathology of asthma. However, there are no 
therapeutics to speciﬁ  cally treat endogenous causes of ASM 
remodeling in asthma.
In contrast it may be possible to speciﬁ  cally treat vascular 
abnormalities in the asthmatic airway. The pro-angiogenic 
molecule mostly studied in asthma is VEGF and studies 
indicate its susceptibility to corticosteroid treatment. Chetta 
and colleagues observed reduction of VEGF after inhalation 
of high doses of ﬂ  uticasone in a subgroup of asthmatic 
patients. Accompanied by the reduction of VEGF, the 
vascular area was signiﬁ  cantly decreased and fewer vessel 
numbers were found.98 Structural and non-resident cells 
are capable of producing VEGF and other pro-angiogenic 
factors. However, in ASM expression of VEGF appears to 
be dexamethasone insensitive unless TGF-β is added as a 
stimulus (regardless of disease state) supporting a direct, 
but interlinked effect of corticosteroids on the reduction of 
this factor (own unpublished data, Figure 1D, F). Further-
more collagen IV expression was increased back to normal 
(baseline levels of sham treated animals) after dexametha-
sone treatment in an acute mouse model of allergic airway 
disease,99 suggesting that corticosteroids not only reduce 
pro-angiogenic but also increase potential ECM derived 
anti-angiogenic factors. In humans endostatin (NC domain 
of collagen XVIII) has been described to be uninﬂ  uenced 
by corticosteroids (beclomethasone dipropionate) treat-
ment, suggesting a shift from a pro-angiogenic towards an 
anti-angiogenic environment in asthmatics.59 Long- or short-
acting β antagonists studies on vascular remodeling are rare 
and effects range from reduction of vascular permeability to 
antiangiogenic properties of salmeterol.100
Conclusion
Remodeling affects airway function in asthma, and is likely 
to contribute to the increased rate of lung function decline Journal of Asthma and Allergy 2009:2 40
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in asthmatics.73 The current therapies used in humans for 
the treatment of asthma do not fully reverse the remodeling 
process, and, in fact, the ﬁ  ndings of reports of in vivo 
treatment are conflicting. In vitro, we and others have 
demonstrated that ECM deposition may in fact be increased 
by corticosteroids.101 Mechanisms of the remodeling process 
need to be better understood to allow the development of 
new therapeutics, which can target this important aspect of 
airways disease.
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